Nebraska News Desk

Grand View Research, Inc. – Market Research And Consulting.

According to a report,“Blockbuster Oncology Brands Market Size, Share & Trends Analysis Report By Brand (Opdivo, Revlimid, Zejula), By Indication (Lung Cancer, Lymphoma, Multiple Myeloma), And Segment Forecasts, 2018 – 2027” , published by Grand View Research, Inc.,The global blockbuster oncology brands market is poised to reach USD 62.80 billion by 2027, progressing at a CAGR of 7.3% during the forecast period. Shift towards immunotherapies coupled with increasing number of indication expansion trials is one of the primary growth stimulants for the market.

Key Takeaways from the report:

• North America dominated the global arena in 2017, with approximately 65.0% share. The region is likely to maintain its position through 2027

• In terms of revenue, the lung cancer segment is estimated to expand at a CAGR of over 9.0% during the forecast period

• The multiple myeloma segment held more than 30.0% of the market revenue in 2017 and is anticipated to lose its position to lung cancer by 2027

• Europe is projected to experience modest growth during the forecast period due to delays in cost-effectiveness analysis, carried out by health technology assessment bodies, slowing approval process and lowering reimbursement

• Some of the key companies present in the market are Tesaro, Inc.; Merck &Co.; Bristol Myers Squibb; AstraZeneca Plc; and Roche Ltd.

Browse More Reports in Pharmaceuticals Industry:

• Plasma Protein Therapeutic Market – Approval of plasma products across multiple indications, increasing R & D activities, and high demand for advanced therapeutic options are anticipated to drive the market growth.
• Antibiotic Resistance Market – High burden of antibiotic-resistant infections and emergence of multi-drug resistant pathogens have been augmenting the market.

Current market analysis reveals Revlimid and Opdivo as bestselling therapies in the marketplace in 2017. However, a robust pipeline will uplift Opdivo’s sales, while Revlimid’s patent expiration will lower its revenue share in the market by 2027. Although Keytruda poses strong competition to Opdivo, especially after bagging a frontline approval for NSCLC in 2017, the immunotherapeutic is expected to trail behind the latter by 2027.

Lifecycle management strategies, including expansion of approved indications and development of combination therapies, underline competitive dynamics in the global blockbuster oncology brands market. Collaborative agreements signed by participating companies facilitate development, commercialization, and regional expansion of products. Such strategies not only enable players to gain easy access into new markets, but also allow them to leverage scientific and technological expertise of their collaborative partner.

Grand View Research has segmented the global blockbuster oncology brands market on the basis of brands, indication, and region:

Blockbuster Oncology Brands Outlook (Revenue, USD Million, 2015 – 2027)

• Opdivo

• Keytruda

• Perjeta

• Ibrance

• Tecentriq

• Gazyva

• Zejula

• Tagrisso

• Darzalex

• Imbruvica

• Revlimid

Blockbuster Oncology Brands Indication Outlook (Revenue, USD Million, 2015 – 2027)

• Lung cancer

• Breast cancer

• Multiple myeloma

• Lymphoma

• Others

Blockbuster Oncology Brands Regional Outlook (Revenue, USD Million, 2015 – 2027)

• North America

  • U.S.

  • Canada

• Europe

  • Germany

  • U.K.

  • Italy

  • Spain

  • France

  • Switzerland

  • Poland

  • Denmark

• Asia Pacific

  • China

  • Japan

  • India

  • Australia

  • New Zealand

  • Philippines

  • Indonesia

  • Hong Kong

  • Singapore

  • South Korea

• Latin America

  • Mexico

  • Brazil

  • Argentina

• Middle East & Africa

• Saudi Arabia

• Israel

• Turkey

Explore the BI enabled intuitive market research database, Navigate with Grand View Compass, by Grand View Research, Inc.

About Grad View Research, Inc.

Grand View Research provides syndicated as well as customized research reports and consulting services on 46 industries across 25 major countries worldwide. This U.S.-based market research and consulting company is registered in California and headquartered in San Francisco. Comprising over 425 analysts and consultants, the company adds 1200+ market research reports to its extensive database each year. Supported by an interactive market intelligence platform, the team at Grand View Research guides Fortune 500 companies and prominent academic institutes in comprehending the global and regional business environment and carefully identifying future opportunities.

For more information: www.grandviewresearch.com

Media Contact
Company Name: Grand View Research, Inc.
Contact Person: Sherry James, Corporate Sales Specialist – U.S.A.
Email: Send Email
Phone: 1-415-349-0058, Toll Free: 1-888-202-9519
Address:201, Spear Street, 1100
City: San Francisco
State: California
Country: United States
Website: www.grandviewresearch.com/industry-analysis/blockbuster-oncology-brands-market